Compare Inovio Pharmaceuticals Inc (INO) vs Super Group (SGHC) Limited Ordinary Shares (SGHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Super Group (SGHC) Limited Ordinary Shares trades at $11.34 (market cap $5.86B). The key difference: Super Group (SGHC) Limited Ordinary Shares is far larger — about 52.2× Inovio Pharmaceuticals Inc's market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.73% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Super Group (SGHC) Limited Ordinary Shares for 0 Days on average.
| INO | SGHC | |
|---|---|---|
Market Cap | $112.19M | $5.86B |
Volume | 3,201,278 | 1,905,788 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $15.59 |
52-Week Low | $0.66 | $8.52 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $83.51M | $5.41B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →
